SCHEMBL300200

SCHEMBL300200

N[C@H](C(=O)O)C(O)CC(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.48
SLCO1B1 Q9Y6L6 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
SLC22A6 Q4U2R8 1/20 0.46
GABRR1 P24046 2/20 0.44
LMNA P02545 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
SLC7A5 Q01650 1/20 0.42
MEN1 O00255 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
SLC1A3 P43003 2/20 0.37
SLC1A2 P43004 2/20 0.37
SLC1A1 P43005 2/20 0.37
GRM8 O00222 1/20 0.37
GRM6 O15303 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13497176 1.00 USP2 (0.48) USP2SLCO1B1SMN1; SMN2SLC22A6GABRR1
SCHEMBL31527767 1.00 USP2 (0.48) USP2SLCO1B1SMN1; SMN2SLC22A6GABRR1
SCHEMBL28410409 1.00 USP2 (0.48) USP2SLCO1B1SMN1; SMN2SLC22A6GABRR1
SCHEMBL300199 1.00 USP2 (0.48) USP2SLCO1B1SMN1; SMN2SLC22A6GABRR1
Ethane SCHEMBL10712982 0.95 USP2 (0.45) USP2SLCO1B1SMN1; SMN2SLC22A6GABRR1
SCHEMBL31154516 0.93 SLC22A6 (0.59) USP2SLCO1B1SMN1; SMN2SLC22A6GABRR1
SCHEMBL4713869 0.85 USP2 (0.56) USP2SLCO1B1SMN1; SMN2SLC22A6GABRR1
SCHEMBL4550634 0.82 USP2 (0.52) USP2SLCO1B1SMN1; SMN2SLC7A5MEN1
SCHEMBL2273519 0.82 USP2 (0.46) USP2SLCO1B1SMN1; SMN2SLC7A5MEN1
SCHEMBL2273513 0.82 USP2 (0.46) USP2SLCO1B1SMN1; SMN2SLC7A5MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 735 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4658249-A1 COMPOSITIONS AND METHODS BioNTech SE (DE) 2025-12-10 EP claimed
US-12378328-B2 Biohybrid peptidoglycan oligomers NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2025-08-05 US claimed
CN-118995783-A Gene recombination engineering strain with malonyl coenzyme A synthesis path using L-glutamic acid as substrate and application thereof 广东以色列理工学院 2024-11-22 CN claimed
WO-2024160828-A1 COMPOSITIONS AND METHODS BioNTech SE (DE) 2024-08-08 WO claimed
CN-117431751-A Pretreatment method for dyeing cotton textiles 康赛妮集团有限公司 2024-01-23 CN claimed
CN-117106189-A Metal organic framework artificial hydrolase and preparation method and application thereof 华南理工大学 2023-11-24 CN claimed
CN-116430049-A Metabolic marker of esophagus cancer and application thereof 汕头大学医学院 2023-07-14 CN claimed
CN-109988312-B Polyamide acid ester, preparation method, negative polyimide composition and application 深圳先进技术研究院 2023-04-11 CN claimed
US-20220213232-A1 BIOHYBRID PEPTIDOGLYCAN OLIGOMERS NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2022-07-07 US claimed
CN-112794806-A Manufacturing process of functional cotton fabric 王晨绚 2021-05-14 CN claimed
US-6472201-B1 GROWING AND TESTING MICROORGANISMS IN A MULTITEST FORMAT WHICH UTILIZES A GEL FORMING MATRIX FOR THE RAPID SCREENING OF CLINICAL AND ENVIRONMENTAL CULTURES BIOLOG, INC. 2002-10-29 US claimed
WO-2001094327-A1 CATALYST COMPRISING SOLUBLE POLYMER AND POLYAMINO ACID STYLACATS LIMITED (GB) 2001-12-13 WO claimed
US-5756650-A COMPOSITION COMPRISING POLYAMIC ACID, CURE ACCELERATOR SELECTED FROM GROUP CONSISTING OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AMINO ACID COMPOUND, AROMATIC COMPOUND HAVING TWO OR MORE HYDROXYL GROUPS KABUSHIKI KAISHA TOSHIBA (JP) 1998-05-26 US claimed
EP-0513068-B1 THREE NEW NON-POLYGLUTAMATABLE DEAZAAMINOPTERINS AND PROCESS FOR PREPARING THE SAME NAIR MADHAVAN G (US) 1995-09-13 EP claimed
EP-0513068-A1 THREE NEW NON-POLYGLUTAMATABLE DEAZAAMINOPTERINS AND PROCESS FOR PREPARING THE SAME. NAIR MADHAVAN G (US) 1992-11-19 EP claimed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP claimed
WO-1991010666-A1 THREE NEW NON-POLYGLUTAMATABLE DEAZAAMINOPTERINS AND PROCESS FOR PREPARING THE SAME NAIR MADHAVAN G (US) 1991-07-25 WO claimed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US claimed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP claimed
EP-0086680-B1 STRONG ANTI-ASTHENIC COMPOSITIONS CONTAINING A DOUBLE SALT OF ASCORBIC ACID AND AMINO-DIACIDS LABORATOIRES MAYOLY SPINDLER (FR) 1985-12-18 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378328-B2 Biohybrid peptidoglycan oligomers NOD2, DDOST, CD14 USP2 3361/4885SLCO1B1 796/4885SMN1; SMN2 4384/4885
US-20220213232-A1 BIOHYBRID PEPTIDOGLYCAN OLIGOMERS NOD2, DDOST, CD14 USP2 3361/4885SLCO1B1 796/4885SMN1; SMN2 4384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.